Wells Fargo
KYTX icon

Wells Fargo’s Kyverna Therapeutics KYTX Stock Holding History

Wells Fargo’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
373,009
+258,610
+226% +$2.3M ﹤0.01% 3191
2026
Q1 		$987K Buy
114,399
+39,450
+53% +$329K ﹤0.01% 3746
2025
Q4 		$705K Buy
74,949
+56,669
+310% +$421K ﹤0.01% 4221
2025
Q3 		$110K Buy
18,280
+14,948
+449% +$59.8K ﹤0.01% 5271
2025
Q2 		$10.2K Sell
3,332
-13,346
-80% -$33K ﹤0.01% 5947
2025
Q1 		$32.2K Sell
16,678
-162,334
-91% -$480K ﹤0.01% 5541
2024
Q4 		$670K Buy
179,012
+25,225
+16% +$121K ﹤0.01% 3987
2024
Q3 		$752K Buy
153,787
+41,078
+36% +$317K ﹤0.01% 3730
2024
Q2 		$845K Buy
112,709
+100,803
+847% +$1.54M ﹤0.01% 3602
2024
Q1 		$296K Buy
+11,906
New +$332K ﹤0.01% 4229

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Wells Fargo's KYTX Position: Q2 2026 in Review

Wells Fargo increased its Kyverna Therapeutics (KYTX) stake by 226% in Q2 2026, buying an estimated $2.3M and bringing the position to 373,009 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3191.

Wells Fargo first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Wells Fargo held 373,009 shares of Kyverna Therapeutics worth $3.32M as of Q2 2026.
  • Wells Fargo bought 258,610 Kyverna Therapeutics shares in Q2 2026, an estimated $2.3M.
  • Kyverna Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3191 holding.
  • Wells Fargo first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.